Efficacy of Retreatments With Intravitreal Bevacizumab
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00406744
Verified November 2006 by Asociación para Evitar la Ceguera en México. Recruitment status was: Recruiting
Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.
Condition or disease
Age Related Macular DegenerationChoroidal Neovascularization
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
60 Years to 95 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
* Any visual acuity
OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
Active angiogram leakage
* Basal Inflammatory disease
Lesions bigger than 5400 u or with scarring greater than 50% of lesion.